Aktis Oncology (NASDAQ:AKTS) Announces Quarterly Earnings Results

Aktis Oncology (NASDAQ:AKTS) released its quarterly earnings data on Thursday. The technology company reported ($0.54) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.47) by ($0.07), FiscalAI reports. The business had revenue of $3.91 million during the quarter, compared to analysts’ expectations of $4.02 million.

Aktis Oncology Stock Performance

NASDAQ:AKTS traded down $0.73 on Thursday, hitting $16.31. 147,094 shares of the stock were exchanged, compared to its average volume of 354,297. The stock has a market capitalization of $876.72 million and a price-to-earnings ratio of -19.93. Aktis Oncology has a 52 week low of $13.96 and a 52 week high of $34.19. The company’s 50-day moving average price is $18.96 and its 200 day moving average price is $20.84.

Wall Street Analysts Forecast Growth

Several analysts have weighed in on the stock. Wall Street Zen cut shares of Aktis Oncology from a “hold” rating to a “sell” rating in a research note on Saturday, July 25th. Oppenheimer began coverage on shares of Aktis Oncology in a research note on Wednesday, September 9th. They issued an “outperform” rating and a $40.00 target price for the company. BMO Capital Markets began coverage on Aktis Oncology in a report on Tuesday, August 18th. They issued an “outperform” rating and a $37.00 target price on the stock. Weiss Ratings lowered Aktis Oncology from a “sell (d+)” rating to a “sell (d)” rating in a research report on Friday, October 2nd. Finally, Wedbush reaffirmed an “outperform” rating and set a $35.00 price target on shares of Aktis Oncology in a report on Friday, October 2nd. One equities research analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $35.62.

Aktis Oncology Company Profile

Aktis Oncology, Inc. is a clinical-stage biotechnology company developing targeted radiopharmaceuticals for solid tumors. Its approach uses small protein-based molecules designed to bind cancer-associated targets and deliver radioactive payloads to tumor cells. The company’s pipeline includes investigational programs directed at targets found on solid tumors, including Nectin-4. These candidates are being developed for potential use in patients with advanced cancers; they are not approved for commercial use.